Jafron Biomedical Co.,Ltd.

SZSE:300529 Rapporto sulle azioni

Cap. di mercato: CN¥23.7b

Jafron BiomedicalLtd Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Fan Dong

Amministratore delegato

CN¥3.7m

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO14.2yrs
Proprietà del CEO45.9%
Durata media del management1.9yrs
Durata media del Consiglio di amministrazione3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Oct 21
Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

Oct 02
Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Sep 09
Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Aug 25
The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

May 28
Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

May 24
A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

May 08
Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02
Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Apr 13
Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Mar 22
Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Mar 04
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

AMMINISTRATORE DELEGATO

Fan Dong (54 yo)

14.2yrs

Mandato

CN¥3,741,000

Compensazione

Mr. Fan Dong serves as Chairman of Board of Directors and General Manager at Jafron Biomedical Co., Ltd. He serves as Director since April 27, 2023 at Jafron Biomedical Co.,Ltd. He served as Company Secret...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Fan Dong
Chairman of Board of Directors & GMno dataCN¥3.74m45.86%
CN¥ 10.9b
Xueyun Liao
Director & Financial Director1.6yrsCN¥500.50k0.019%
CN¥ 4.5m
De Zhi Li
Deputy General Managerno dataCN¥865.40k0.46%
CN¥ 108.4m
Xian Min Tang
Deputy GM & Directorno dataCN¥2.65m2.76%
CN¥ 653.1m
Aijun Wu
Deputy General Manager4.5yrsCN¥2.44m0.031%
CN¥ 7.4m
Rui Wang
General Manager1.2yrsCN¥510.40kNessun dato
Cong Huang
Board Secretary2.2yrsCN¥455.20k0.00044%
CN¥ 104.3k

1.9yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 300529 non è considerato esperto (durata media 1.9 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Fan Dong
Chairman of Board of Directors & GM14.2yrsCN¥3.74m45.86%
CN¥ 10.9b
Xueyun Liao
Director & Financial Directorless than a yearCN¥500.50k0.019%
CN¥ 4.5m
Xian Min Tang
Deputy GM & Director14.2yrsCN¥2.65m2.76%
CN¥ 653.1m
Claudio Ronco
Member of Global Advisory Board3.4yrsNessun datoNessun dato
Feng Li
Non-Independent Director4.6yrsCN¥1.08m0.099%
CN¥ 23.4m
Xiaohong Peng
Chairman of Supervisory Board4.6yrsNessun datoNessun dato
Wen Lei
Non-Independent Director4.6yrsCN¥177.20kNessun dato
Rinaldo Bellomo
Member of Global Advisory Board3.4yrsNessun datoNessun dato
Thomas Rimmelé
Member of Global Advisory Board3.4yrsNessun datoNessun dato
John Prowle
Member of Global Advisory Board3.4yrsNessun datoNessun dato
Antoine Schneider
Member of Global Advisory Board3.4yrsNessun datoNessun dato
Olivier Joannes-Boyau
Member of Global Advisory Board3.4yrsNessun datoNessun dato

3.4yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300529 sono considerati esperti (durata media dell'incarico 3.4 anni).